These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 24173586)

  • 1. Clinical safety and pharmacology trial.
    Mauck C; Thurman A; Schwartz J
    Curr Top Microbiol Immunol; 2014; 383():79-95. PubMed ID: 24173586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical safety evaluation.
    Holt JD; Nuttall JP
    Curr Top Microbiol Immunol; 2014; 383():55-78. PubMed ID: 23612993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Microbicides for prevention of HIV infection: clinical efficacy trials.
    Abdool Karim SS; Baxter C
    Curr Top Microbiol Immunol; 2014; 383():97-115. PubMed ID: 23695725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rectal microbicide development.
    McGowan I; Dezzutti C
    Curr Top Microbiol Immunol; 2014; 383():117-36. PubMed ID: 23612991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of topical microbicides to prevent HIV-1 transmission: concepts, testing, lessons learned.
    Friend DR; Kiser PF
    Antiviral Res; 2013 Sep; 99(3):391-400. PubMed ID: 23845918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candidate microbicides and their mechanisms of action.
    Herrera C; Shattock RJ
    Curr Top Microbiol Immunol; 2014; 383():1-25. PubMed ID: 23612992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application studies of animal models in evaluating safety and efficacy of HIV-1 microbicides].
    Zhu L; Zhang GH; Zheng YT
    Dongwuxue Yanjiu; 2010 Feb; 31(1):66-76. PubMed ID: 20446456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New HIV drugs show promise in early studies.
    McCarthy M
    Lancet; 2002 Mar; 359(9308):767. PubMed ID: 11888592
    [No Abstract]   [Full Text] [Related]  

  • 9. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1.
    Pirrone V; Wigdahl B; Krebs FC
    Antiviral Res; 2011 Jun; 90(3):168-82. PubMed ID: 21439325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microbicide dosage forms.
    Rohan LC; Devlin B; Yang H
    Curr Top Microbiol Immunol; 2014; 383():27-54. PubMed ID: 24220751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
    Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
    Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.
    Wainberg MA; Sawyer JP; Montaner JS; Murphy RL; Kuritzkes DR; Raffi F
    Antivir Ther; 2005; 10(1):13-28. PubMed ID: 15751760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Improved long-term success. New nucleoside for once daily combinations].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043
    [No Abstract]   [Full Text] [Related]  

  • 14. Microbicides for multidrug-resistant and multitropic HIV-1.
    D'Cruz OJ; Uckun FM
    Curr Opin Investig Drugs; 2008 Feb; 9(2):152-69. PubMed ID: 18246518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of dapivirine vaginal ring for HIV prevention.
    Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
    Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Electrospun fibers for vaginal anti-HIV drug delivery.
    Blakney AK; Ball C; Krogstad EA; Woodrow KA
    Antiviral Res; 2013 Dec; 100 Suppl():S9-16. PubMed ID: 24188701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microbicide research in developing countries: have we given the ethical concerns due consideration?
    Moodley K
    BMC Med Ethics; 2007 Sep; 8():10. PubMed ID: 17877834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing regulatory strategy for microbicides.
    Nardi R; Arterburn L; Carlton L
    Curr Top Microbiol Immunol; 2014; 383():137-52. PubMed ID: 24126799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers.
    Doncel GF; Clark MR
    Antiviral Res; 2010 Dec; 88 Suppl 1():S10-8. PubMed ID: 21109063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
    van Lunzen J
    Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.